← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06466538

NCT06466538 Investigate"Clinically" the Effectiveness of Boswellia Based Intracanal Medication Compared to Calcium Hydroxide Ca(OH)2 and Ledermix on the Levels of Bacteria and Inflammatory Cytokines in Root Canals and Periradicular Tissues of Teeth With Apical Periodontitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06466538
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Mansoura University
Condition Microbial Colonization
Study Type INTERVENTIONAL
Enrollment 36 participants
Start Date 2022-06-01
Primary Completion 2024-07-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Calcium hydroxideLeddermixBoswellia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 36 participants in total. It began in 2022-06-01 with a primary completion date of 2024-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to investigate "clinically" the effectiveness of Boswellia based intracanal medication compared to the commonly used intracanal medicaments (calcium hydroxide Ca(OH)2 and Ledermix) on the levels of bacteria and inflammatory cytokines in root canals and periradicular tissues of teeth with apical periodontitis.

Eligibility Criteria

Inclusion Criteria: * Single-rooted with pulp necrosis and apical periodontitis. * The age range from 20 to 60 years Exclusion Criteria: * Receiving antibiotic treatment within the preceding 3 months. * Reporting systemic disease. * Teeth that could not be isolated with rubber dam. * Teeth with periodontal pockets deeper than 3 mm.

Contact & Investigator

Central Contact

May Abuzoor, phD

✉ drmayzoor@hotmail.com

📞 0096599182767

Principal Investigator

Amany Badr, Professor

STUDY CHAIR

Mansoura University

Frequently Asked Questions

Who can join the NCT06466538 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Microbial Colonization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06466538 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06466538 currently recruiting?

Yes, NCT06466538 is actively recruiting participants. Contact the research team at drmayzoor@hotmail.com for enrollment information.

Where is the NCT06466538 trial being conducted?

This trial is being conducted at Al Mansurah, Egypt.

Who is sponsoring the NCT06466538 clinical trial?

NCT06466538 is sponsored by Mansoura University. The principal investigator is Amany Badr, Professor at Mansoura University. The trial plans to enroll 36 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology